glp 1 hba1c reduction Oral GLP-1 reduces body weight, for adults with obesity plus type 2 diabetes Glucagon-like peptide-1 receptor: mechanisms and

Key agents include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound

Ozempic and Wegovy were first put on the drug shortage list in August and May of 2022, respectively, because of a surge in demand

Systemic corticosteroids became necessary for treating severe cases of injection-site reactions, which typically would resolve on their own

Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US

In fact, some early studies and patient reports indicate bloating and abdominal discomfort improve on GLP-1 therapy, likely due to the slowed, more gradual digestive process